XML 68 R44.htm IDEA: XBRL DOCUMENT v3.20.4
Collaboration and Other Agreements - Incyte Corporation (Details) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended 24 Months Ended 39 Months Ended
Oct. 31, 2017
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2018
Dec. 31, 2020
Collaboration and Other Agreements [Line Items]            
Revenues   $ 104,883 $ 64,188 $ 60,121    
Incyte MGA012 Agreement | Incyte Corporation (Incyte)            
Collaboration and Other Agreements [Line Items]            
Amounts recognized   40,000   15,000   $ 55,000
Amount of development progress recognized           $ 10,000
Transaction price $ 154,000          
Clinical trial activities selling price amount         $ 4,000  
Maximum | Incyte MGA012 Agreement | Incyte Corporation (Incyte)            
Collaboration and Other Agreements [Line Items]            
Potential development and regulatory milestone payments 420,000          
Potential commercial milestone payments $ 330,000          
Potential proceeds from royalties percent 24.00%          
Minimum | Incyte MGA012 Agreement | Incyte Corporation (Incyte)            
Collaboration and Other Agreements [Line Items]            
Potential proceeds from royalties percent 15.00%          
Revenues From License Agreements | Incyte MGA012 Agreement | Incyte Corporation (Incyte)            
Collaboration and Other Agreements [Line Items]            
Revenues $ 150,000 40,000 100 18,800    
Revenues From License Agreements | Incyte MGA012 Clinical Services | Incyte Corporation (Incyte)            
Collaboration and Other Agreements [Line Items]            
Revenues   8,600 $ 22,100 $ 22,200    
Revenues From License Agreements | Incyte MGA012 Supply Agreement | Incyte Corporation (Incyte)            
Collaboration and Other Agreements [Line Items]            
Revenues   $ 1,400